This website uses cookies

This website uses cookies to ensure you get the best experience. By using our website, you agree to our Privacy Policy

International In-house Counsel Journal logoInternational In-house Counsel Journal logo
Back to library search

Developing Effective Processes to Manage Risk in M&A Transactions

Abstract

By their very nature, merger and acquisition (M&A) transactions can be unwieldy and complicated. The number of people involved and the different functional areas involved seem to grow exponentially as transaction size increases, and each person or functional area brings a different viewpoint and agenda to the table. The timeline is frequently aggressive and sometimes driven by considerations not within the control of the parties. The opportunities and risks are often sizeable and sometimes involve complicated cross-border elements. To complicate matters even further, the term “M&A” includes a wide variety of transactions, from strategic equity or debt investments or small asset purchases all the way up to multi-billion dollar, acquisitions with worldwide impact. All of these factors create inherent risk in M&A transactions, clearly at a legal level but also at a business level. This article lays out some considerations in the form of a multi-step approach, to help manage this risk.

Author

Derek Devgun
Senior Legal Specialist Mergers and Acquisitions, Medtronic Inc., USA

Senior Legal Specialist, managing and coordinating legal work and legal teams (both in-house lawyers and outside legal counsel) in support of Medtronic Corporate Development and business unit teams in all aspects of world-wide M&A/business development activities (acquisitions, divestitures, strategically-driven minority investments and large licensing transactions – pre-transaction support, due diligence, transaction structuring, document drafting and negotiation, and closing) Representative transactions include: U.S. private company acquisitions with and without earnout structures; U.S. public company acquisitions; acquisitions of outside-US private companies; carve-out divestitures of non-strategic global business unit and product lines to private equity firms; secured loans to, and pre-negotiated acquisition agreement with, private OUS company; and numerous other M&A, divestiture, strategic investment and strategic loan transactions (both U.S./domestic and international)

Company

Medtronic Inc.

Medtronic is the world’s largest medical technology company, offering an unprecedented breadth and depth of innovative therapies to fulfill our Mission of alleviating pain, restoring health, and extending life. Last year, more than 8 million people relied on our medical therapies, which treat cardiac and vascular diseases, diabetes, and neurological and musculoskeletal conditions.

Related Papers

Anatomy of a Deal: Good Things Come in Small (and Very Complicated) Packages
Acorda is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Acorda recently completed the acquisition of Biotie Therapies, a...Read more
Portrait image of Jane Wasman
Jane Wasman
President, International & General Counsel, Acorda Therapeutics, USA
Portrait image of Andrew Mayer
Andrew Mayer
Vice President, Legal, Acorda Therapeutics, USA
Mergers and Acquisitions Regulation in Cambodia: A Review of the Revised Law Governing Business Combinations
Over the last decade, the Kingdom of Cambodia has continued to increase its attractiveness to international investors both through consistent economic growth and the on-going reform of its regulatory environment...Read more
Portrait image of Joseph Lovell
Joseph Lovell
Managing Director, IAO Asia, Cambodia
AI and Inventorship
Artificial intelligence (AI) is a cutting-edge technology that has been generating substantial attention worldwide recently, including in the patent community. Balancing the rapid development in AI and adapting the patent...Read more
Portrait image of Anagha Tendulkar
Anagha Tendulkar
In-house Patent Counsel, Cipla, India
REMS Patents: Listability and Other Issues
Abstract: Are Risk Evaluation and Mitigation Strategy (REMS) patents Orange Book listable (or even should be)? A straightforward question with a lot of disagreement. This paper discusses recent litigation on...Read more
Portrait image of Joanna Brougher
Joanna Brougher
Owner & Principal, BioPharma Law Group PLLC, USA
Portrait image of Tom Irving
Tom Irving
Partner, Marbury Law Group, USA
Portrait image of Stacy Lewis
Stacy Lewis
Law Clerk, Finnegan, USA
Portrait image of Mark Feldstein
Mark Feldstein
Partner, Finnegan, USA
Portrait image of Adriana Burgy
Adriana Burgy
Finnegan, USA